Our promising pipeline of
innovative product candidates are
designed to target and help resolve
serious unmet medical needs
Pushing the boundaries of breakthrough therapies
Summit is initiating development activities for SMT112 and will do so first in NSCLC indications.
Summit plans to start treating patients in clinical studies by the second quarter of 2023.
Focused on innovations leveraging deep leadership expertise in discovery with novel development platforms.
*Phase I and II has been completed by our partner Akeso, Phase III clinical studies are planned to be initiated either independently or jointly with our partner Akeso in 2023/24